On December 16th, Eli Lilly and Sinovac Biotech jointly announced the launch of Eli Lilly's non covalent (reversible) BTK inhibitor, Jepanil&Co., Ltd; reg; (Pitobutertinib 100mg and 50mg tablets) in ...